Related Experiment Video
Updated: Jul 29, 2026
12:24
Murine Model of CD40-activation of B cells
Published on: March 5, 2010
Antibody against CD20 in patients with B cell malignancy.
P J Adamson1, H Zola, I C Nicholson
1Child Health Research Institute, Women's and Children's Hospital, University of Adelaide, 72 King William Road, Adelaide 5006, Australia.
Leukemia Research
|October 31, 2001
Summary
Individuals with B cell malignancy or Sjogren's syndrome can produce antibodies against CD20. Screening donors for these autoantibodies is crucial for developing targeted cancer therapies and antibody libraries.
Area of Science:
- Immunology
- Oncology
- Autoimmunity
Background:
- Cancer patients can develop antibodies against tumor-associated antigens.
- B cell malignancies and autoimmune diseases are associated with autoantibody production.
- Phage display antibody libraries offer a method for developing targeted cancer therapies.
Purpose of the Study:
- To investigate the presence of antibodies against CD20 in patients with B cell malignancy or Sjogren's syndrome.
- To assess the potential of these patient populations as sources for antibody library construction.
Main Methods:
- Screening of plasma and serum samples from patients and healthy controls.
- Detection of antibodies targeting the B cell membrane antigen CD20.
Main Results:
- Most samples exhibited low reactivity to CD20.
- A subset of individuals demonstrated significant and reproducible binding to CD20.
- This suggests potential donors for antibody library development exist within these patient groups.
Conclusions:
- Screening for autoantibodies against specific antigens, like CD20, is essential for identifying suitable donors for phage display antibody library construction.
- This approach can aid in the development of novel therapeutics targeting cancer-associated antigens.
